AstraZeneca COVID Monoclonal Combination Headed To Clinic ‘Within Weeks’
Executive Summary
AstraZeneca devoted a surprisingly large piece of its testimony at the recent House vaccine hearing to its therapeutic work. The company appears to be anticipating another shift in public attention back to the mAB cocktail as a way to treat and prevent COVID-19.